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Abstracts / Journal of Nutrition & Intermediary Metabolism 1 (2014) 1e55 7pseudocereals. The available evidence is largely inferential and based on
laboratory studies. Favourable physiological responses have been
demonstrated in animals, but randomised controlled trials in humans are
few, small in scale and the ﬁndings inconsistent.
In contrast, elite cereal varieties with enhanced nutritional attributes, such
as high-ﬁbre barleys that deliver scientiﬁcally substantiated health bene-
ﬁts, are now either on the market or in the development pipeline.
Importantly, these nutritional traits are expressed in high yielding modern
cultivars. The resultant products show great promise in meeting growing
consumer demand for healthier, affordable grain-based foods.
As wholegrains, pseudocereals are nutrient-dense foods that provide more
options for consumers seeking to improve the nutritional quality and va-
riety of their diets, especially individuals on a gluten-free diet. However,
further research is required to elucidate and substantiate the health ben-
eﬁts of pseudocereals.
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Seaweeds, or marine macroalgae have long been a part of the human diet
(1). Coastal harvesting and transport of macroalgae inland for food use still
occurs today in South America. In this way, inland populations avoid iodine
deﬁciency and enjoy sea vegetables in their diet. Marine macroalgae have
also been used as medicines by ancient civilizations such as those at Monte
Verde in Chile, a site that dates back an astonishing 12,000 years (2).
Marine macroalgae are a rich source of colloids that are used in foods and
pharmaceuticals. The main commercial ‘phycocolloids’ are agar, alginate
and carrageenan, familiar as thickening agents in foods. Aside from these
colloids, there is a remarkable array of bioactives in current use or devel-
opment. These include carbohydrate compounds such as b-glucan and
fucoidan, in addition to pigments like fucoxanthin and polyphenols (3).
Marinova is an Australian manufacturer of fucoidan. Fucoidan is a non-
gelling sulfated fucose rich polysaccharide found only in brown macro-
algae. It is non-toxic, yet displays marked bioactivity as an anti-viral, anti-
bacterial, anti-inﬂammatory and immunomodulatory compound. Several
new studies point to potential as an adjunct to cancer therapies (4).
Historically, fucoidanwas used as a selectin blocking agent. Selectins are cell
surface receptors on white blood cells that perform a ‘braking function’ for
the cells, allowing them to roll on an organs endothelial surface and ulti-
mately enter that tissue space. Fucoidan inhibits ‘P’ and ‘L’ selectins and thus
leukocyte adhesion and rolling thereby reducing inﬂammation in tissues. A
new animal health product demonstrates this direct anti-inﬂammatory
activity. Thoroughbred horses are at risk of gastric ulceration during periods
away from a natural grazing environment and oral fucoidan has a calmative
effect and reduces the need for pharmaceutical intervention.
The anti-viral activity of fucoidan is caused by receptor blocking activity,
rather than a virucidal action. Fucoid an prevents the entry of viruses to
cells, thereby preventing viral replication. Fucoidan from Undaria pinna-
tiﬁda (commonly known as wakame), is a highly effective inhibitor of
clinical strains of herpes viruses, including those resistant to acyclovir (4).
A similar level of inhibitory activity is seen in strains of inﬂuenza viruses
demonstrating fucoidan has excellent potential as an anti-viral agent.
Fucoidan also inhibits the adhesion of the stomach ulcer causative agent
Helicobacter pylori. In recent studies, fucoidan compounds were demon-
strated to signiﬁcantly reduce adhesion to gastric cells in vitro. There is a
need for novel approaches to treating Helicobacter pylori infection as
resistance to current antibiotics increases. Fucoidan compounds offer a
new strategy as adjunct therapies.
Fucoidan stimulates both innate and speciﬁc immunity and can be ther-
apeutically useful. Immunomodulation by fucoidan has been reported by a
number of research groups. For example, in a double blind placebo
controlled trial, fucoidan increased the immune response to seasonal
vaccination in an elderly population (5).
Lastly, a co-extracted fucoidan containing a large concentration of poly-
phenol has been developed by Marinova. This has a remarkable level of
antioxidant activity directed against the superoxide anion - the main
precursor of free radicals. This free radical neutralising activity togetherwith the anti-inﬂammatory nature of fucoidan makes the extract thera-
peutically appealing. In a clinical trial with topical application of this
extract, there were signiﬁcant inhibitory effects of UV damage, in addition
to signiﬁcant reductions in age related pigmentation.
To conclude, whole seaweeds, and specialty compounds derived from
seaweeds have great value in foods, supplements, pharmaceuticals and
animal health applications. Future research into these compounds holds
great promise for novel products.
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Plant oils are an important source of dietary fat and represent as much as
25% of human caloric intake in developed countries. The current annual
world production of plant oils is about 120 million tonnes, with a value of
over US$65 billion, of which 86% is used for human consumption and the
rest utilised in industrial applications. Fatty acids are the major constitu-
ents of plant oils and represent an impressive renewable resource of cal-
ories and nutrients. In nature there is an enormous diversity of fatty acids
however current commercial plant oils are comprised of relatively few
fatty acids. The ability to genetically engineer most commercial oilseed
species and an explosion in the knowledge of genes controlling the syn-
thesis of fatty acids have combined to enable the application of metabolic
engineering for the production of plant oils with enhanced nutritional
properties. This talk will discuss strategies being employing in the Oilseed
Group at CSIRO for the development of nutritionally improved plant oils.
These include the use of RNAi gene silencing for the creation of low
saturated and low cyclopropane, highly monounsaturated forms of cot-
tonseed oil.
I will also discuss the production of long chain n-3 PUFAs EPA and DHA in
plant oil. Long-chain n-3 PUFAs such as EPA and DHA found in ﬁsh oil are
recognised for their strong health beneﬁts. These include cardiovascular
protection, joint mobility and cognitive enhancement in infants. EPA and
DHA are used in a wide range of applications ranging from aquaculture
feed (ﬁsh do not synthesise these fatty acids but rather accumulate them
in their diet), food nutraceutical additives, through to highly enriched
pharmaceuticals. Demand for these fatty acids has grown rapidly and it is
now recognised that wild-caught ﬁsh supply will not meet future de-
mand. Demand for these fatty acids is growing rapidly and a sustainable
source is required. Oilseed crops could provide a low cost, highly scalable
solution if the native fatty acid pathways can be extended to produce
marine-type n-3 fatty acids. The CSIRO Oilseed group has recently suc-
ceeded in metabolically engineering oilseeds to contain ﬁsh oil like levels
of DHA. This work required the discovery (from algae), introduction and
coordinated expression of transgenes encoding an entire biosynthetic
pathway comprising seven discrete enzymatic conversion steps, one of
the most complex pathway engineering so far achieved in plants. Prog-
ress in developing a DHA canola crop for commercialisation will be
discussed.
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